Solventum Corporation (NYSE:SOLV) Receives Average Rating of “Hold” from Analysts

Solventum Corporation (NYSE:SOLV) has earned an average recommendation of “Hold” from the thirteen brokerages that are presently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, five have issued a hold recommendation and seven have issued a buy recommendation on the company. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $90.6364.

Several research analysts have commented on SOLV shares. Rothschild & Co Redburn initiated coverage on shares of Solventum in a research report on Tuesday, March 24th. They set a “sell” rating and a $60.00 price objective for the company. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Solventum in a report on Tuesday, January 27th. Piper Sandler reiterated an “overweight” rating on shares of Solventum in a research note on Wednesday, December 17th. Wall Street Zen cut Solventum from a “buy” rating to a “hold” rating in a report on Sunday, March 8th. Finally, BTIG Research restated a “buy” rating and set a $100.00 price objective on shares of Solventum in a research report on Friday, February 27th.

Solventum Stock Performance

SOLV opened at $63.60 on Friday. The business has a fifty day simple moving average of $71.49 and a 200 day simple moving average of $75.18. The company has a market capitalization of $11.03 billion, a PE ratio of 7.17, a price-to-earnings-growth ratio of 1.04 and a beta of 0.71. Solventum has a 1 year low of $60.70 and a 1 year high of $88.20. The company has a debt-to-equity ratio of 1.00, a current ratio of 1.23 and a quick ratio of 0.89.

Solventum (NYSE:SOLV) last issued its quarterly earnings data on Thursday, February 26th. The company reported $1.57 earnings per share for the quarter, topping the consensus estimate of $1.50 by $0.07. The business had revenue of $2 billion during the quarter, compared to analysts’ expectations of $1.96 billion. Solventum had a net margin of 18.69% and a return on equity of 25.26%. The business’s revenue was down 3.7% on a year-over-year basis. During the same quarter in the previous year, the company earned $1.41 EPS. Solventum has set its FY 2026 guidance at 6.400-6.600 EPS. Research analysts expect that Solventum will post 6.58 EPS for the current year.

Insider Activity

In other news, Director Amy Mcbride Wendell bought 1,475 shares of the stock in a transaction on Tuesday, March 10th. The stock was acquired at an average price of $68.03 per share, with a total value of $100,344.25. Following the acquisition, the director directly owned 5,039 shares in the company, valued at approximately $342,803.17. This trade represents a 41.39% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 0.05% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the stock. United Services Automobile Association acquired a new position in shares of Solventum during the 1st quarter valued at $239,000. Woodline Partners LP grew its holdings in Solventum by 40.7% in the first quarter. Woodline Partners LP now owns 11,677 shares of the company’s stock worth $888,000 after purchasing an additional 3,377 shares during the period. Intech Investment Management LLC grew its holdings in Solventum by 167.0% in the first quarter. Intech Investment Management LLC now owns 16,669 shares of the company’s stock worth $1,268,000 after purchasing an additional 10,425 shares during the period. New York State Common Retirement Fund increased its stake in Solventum by 1.6% in the second quarter. New York State Common Retirement Fund now owns 68,601 shares of the company’s stock valued at $5,203,000 after purchasing an additional 1,052 shares in the last quarter. Finally, CW Advisors LLC raised its holdings in shares of Solventum by 6.1% during the second quarter. CW Advisors LLC now owns 4,375 shares of the company’s stock valued at $332,000 after purchasing an additional 253 shares during the period.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.